Novel Targeted Therapies in Adrenocortical Carcinoma

Rákkutatás · Adrenocortical carcinoma · TP53 · EGFR

Progress is being made in the fight against adrenocortical carcinoma with the identification of new therapeutic targets and new means by which to attack them.

Adrenocortical carcinoma is a rare cancer with a poor prognosis due to its aggressive nature and resistance to conventional chemotherapy. Over the past 12 years there has been renewed interest in developing new therapies, including identifying key signaling nodes responsible for cell proliferation. Clinical trials of tyrosine kinase inhibitors as monotherapy have generally been disappointing, although exceptional responders may highlight subsets that may benefit. Agents targeting the Wnt signaling pathway have been developed, although not yet used specifically for adrenal cancer. Inhibitors of ACAT1 and tools to target SF1, mTOR and other proteins are moving towards clinical application. Progress is being made in the fight against adrenocortical carcinoma with the identification of new therapeutic targets and new means by which to attack them.

Accurate and effective treatments are urgently needed for adrenocortical carcinoma, a rare but highly aggressive malignancy that currently lacks curative systemic therapies. Developing novel targeted agents could improve survival and quality of life for patients with limited options.

Bizonyítékszint: Számítógépes vagy elméleti. Modellből vagy adatbányászatból származó jel.

Eredeti forrás

Kapcsolódó jelek